Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Serkan Sertel

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Proceedings of the National Academy of Sciences of the United States of America|August 3, 2011
In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humansElina Erikson, Tarek Adam, Sarah Schmidt, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|January 23, 2019
Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2)Cornelia von Hagens, Ingeborg Walter-Sack, Maren Goeckenjan, et al.
Breast Cancer Research and Treatment|April 26, 2017
Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2)Cornelia von Hagens, Ingeborg Walter-Sack, Maren Goeckenjan, et al.
Nature Medicine|September 14, 2012
SAMHD1 restricts HIV-1 infection in resting CD4(+) T cellsHanna-Mari Baldauf, Xiaoyu Pan, Elina Erikson, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Proceedings of the National Academy of Sciences of the United States of America|August 3, 2011
In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humansElina Erikson, Tarek Adam, Sarah Schmidt, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|January 23, 2019
Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2)Cornelia von Hagens, Ingeborg Walter-Sack, Maren Goeckenjan, et al.
Breast Cancer Research and Treatment|April 26, 2017
Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2)Cornelia von Hagens, Ingeborg Walter-Sack, Maren Goeckenjan, et al.
Nature Medicine|September 14, 2012
SAMHD1 restricts HIV-1 infection in resting CD4(+) T cellsHanna-Mari Baldauf, Xiaoyu Pan, Elina Erikson, et al.
Pageof 4